Member Info for BuenaVista

It certainly would Icecool and, tbh, I didn't think of that. In parallel or overlapping. Would be a lot of data to QA though on the remaining time. Anyway, 🤞🏻 they are able to do it. But they must start first!

"3.5 months for a short 2w study is doable...question is will they still tell us when first 3 dosed"

The proposed Q2W study has up to 4 cohorts. They'll never do that and produce the read out by the end of June. One cohort, two at an absolute pinch.

But to complete any cohorts they'll have to start dosing patients. Talk of long lead in times before starting to dose patients doesn't apply here because everything is set up (resources allocated) ready to go as can be witnessed by the previous cohorts and how quickly some of them completed.

What it shows is that the long-standing directors are not prepared to put their own money where their mouths are.

I'd say TG is well out of his depth as well. No experience in finances of a pharma business - as we've seen. No belief in the futue of the company enough to dip his hand in his pocket for even a single Director share.

@Bella, "1a/b (2w) is an inserted trial...if it too proves to be safe they will decide how Phase 2 proceeds etc."

From the 28 Feb RNS: "The dose expansions are expected to begin in H2 2024 in the USA, followed by the Phase 2 efficacy study, subject to funding and FDA approval, which the Board considers to be a major value-driving event for the Group. The dose expansions are expected to be in several orphan indications including soft tissue sarcomas and the selection of these dose expansion indications will be informed by data from the ongoing two-weekly and three-weekly dose escalation studies."

The two-weekly Arm 2 is a Phase 1a dose escalation study.

The dose expansion is a Phase 1b study. They are not the same and not one trial.

The timelines given in the 28 Feb RNS are a nonsense.

Which would be preceisely why this platform needs to be put in the hands of a pharma company that has the finances to take products to market without any of what you say are delays due to lack of funding.

End of Q2 for read outs is still a nonsense.

You realise that the timelines in the 28 Feb RNS are a nonsense and the trial progress reported there is the same as in the 13 December presentation?

It's a jolly for him. Was going anyway but now expenses paid by Avacta. If there were paradigm-shifting data to report, Dr Tap would be presenting to a conference room full of the top pharma people.

But how many US patients have been dosed so far? One? Dumb decisoin to go all US with the clinical development plan. Sucked in by the Americans and sold down the river.

He needs to get onto the people at Suntory.

...I'm pretty sure. Well, at least it is relevant and, as a 'methods' patent, could be applied to the way the current AVA6000 trial is conducted.

GB202318971D0

https://patents.google.com/patent/GB202318971D0/

https://www.ipo.gov.uk/p-ipsum/Case/ApplicationNumber/GB2318971.5

The patent has not been published yet so no further details are available. This notification by the UK IPO is just acknowledgement that it is in the system. This is the system - https://assets.publishing.service.gov.uk/media/62b014a4e90e0765d348809c/Patents-Timeline.pdf - so it looks like it won't be published until some 18 months after the filing date of 12 December 2023.

CC was the CMO ab interim.

I think Avacta are using the term 'ongoing' for their two-weekly study in the same way I would use 'ongoing' to describe my novel, my acting career and my flight to Mars.

"Obviously Cohort 7 will be a gamechanger, either proving the technology works well or not so well."

I think what we've seen so far throughout the cohorts is the emerging RISK (side-effects, toxicity) vs BENFITS (efficacy) profile and I expect C7 to fall into line - more efficacy but also more, and more serious, side-effects.

The platform works, but the dosing needs to be tweaked for different cancers depending, inter alia, on FAP concentration and rate of tumour growth. IF they ever get the fornightly dosing study started, and include several different cancers then that should provide data to inform the best dosing strategy for each cancer. It was encouraging to see pancreatic cancer included in the list of FAPhigh cancers in Phase 1 in the 13 December presentation. However the 28 February RNS states "The dose expansions {i.e. Phase 1b] are expected to be in several orphan indications including soft tissue sarcomas and the selection of these dose expansion indications will be informed by data from the ongoing two-weekly and three-weekly dose escalation studies." so these other orphan indications need to be spelt out, including what they mean in terms of FDA recognition as orphan indications.

The patent referred to is IMHO highly likely to be an ex vivo diagnostic method for determining active FAP, possibly using an Affimer.

That patent is not what was being referred to for the simple reason that the patent describes new chemical compounds (therapeutic conjugates) that would be administered to humans and the AVA6000 trial is for AVA6000 and only AVA6000.

Tbf, you only have AS's word that Affimers are far superior to Optimers.🤔

Affimers are proteins (amino acid chains)

Optimers are nucleic acids (nucleotide chains) but shorter than mAbs (also nucleotide chains)

Could it be that AS and Avacta have been stitched up by the Americans? Taken up a blind alley and sold a pup with this 'short' fortnightly dosing study that is permanently in 'screening' in the US? Who are CC, WT and LC really working for? Avacta should have at least included the MHRA and patients in the UK in this study. They might have found 3 patients by now if they'd done that.

😂😂😂 🤡

"who is the European speciality fund...???" - You've already decided who it is haven't you?

"And why is there a vote on the Rex fundraise...?" - Because the number of shares to be issued exceeds the BoD's authority to issue such shares. That is why some of the II's share allocation also has to be authorised by shareholders.

And yet every day you post gibberish under yet another 'Trading' heading.